PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GNFT vs. MRK
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GNFT and MRK is 0.07, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

GNFT vs. MRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Genfit (GNFT) and Merck & Co., Inc. (MRK). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%60.00%SeptemberOctoberNovemberDecember2025February
-1.69%
-19.11%
GNFT
MRK

Key characteristics

Sharpe Ratio

GNFT:

0.04

MRK:

-1.20

Sortino Ratio

GNFT:

0.51

MRK:

-1.55

Omega Ratio

GNFT:

1.07

MRK:

0.78

Calmar Ratio

GNFT:

0.03

MRK:

-0.86

Martin Ratio

GNFT:

0.09

MRK:

-1.84

Ulcer Index

GNFT:

24.75%

MRK:

14.78%

Daily Std Dev

GNFT:

64.66%

MRK:

22.69%

Max Drawdown

GNFT:

-88.42%

MRK:

-68.62%

Current Drawdown

GNFT:

-84.44%

MRK:

-31.56%

Fundamentals

Market Cap

GNFT:

$186.65M

MRK:

$229.54B

EPS

GNFT:

$0.38

MRK:

$4.78

PE Ratio

GNFT:

9.84

MRK:

18.98

Total Revenue (TTM)

GNFT:

$91.65M

MRK:

$48.59B

Gross Profit (TTM)

GNFT:

$90.79M

MRK:

$36.68B

EBITDA (TTM)

GNFT:

$48.01M

MRK:

$19.73B

Returns By Period

In the year-to-date period, GNFT achieves a 7.40% return, which is significantly higher than MRK's -9.86% return.


GNFT

YTD

7.40%

1M

5.00%

6M

-1.72%

1Y

4.18%

5Y*

-25.25%

10Y*

N/A

MRK

YTD

-9.86%

1M

-10.08%

6M

-19.11%

1Y

-27.40%

5Y*

5.20%

10Y*

8.07%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GNFT vs. MRK — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNFT
The Risk-Adjusted Performance Rank of GNFT is 4747
Overall Rank
The Sharpe Ratio Rank of GNFT is 4747
Sharpe Ratio Rank
The Sortino Ratio Rank of GNFT is 4646
Sortino Ratio Rank
The Omega Ratio Rank of GNFT is 4545
Omega Ratio Rank
The Calmar Ratio Rank of GNFT is 4747
Calmar Ratio Rank
The Martin Ratio Rank of GNFT is 4747
Martin Ratio Rank

MRK
The Risk-Adjusted Performance Rank of MRK is 33
Overall Rank
The Sharpe Ratio Rank of MRK is 11
Sharpe Ratio Rank
The Sortino Ratio Rank of MRK is 44
Sortino Ratio Rank
The Omega Ratio Rank of MRK is 44
Omega Ratio Rank
The Calmar Ratio Rank of MRK is 33
Calmar Ratio Rank
The Martin Ratio Rank of MRK is 11
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GNFT vs. MRK - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Genfit (GNFT) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for GNFT, currently valued at 0.04, compared to the broader market-2.000.002.004.000.04-1.20
The chart of Sortino ratio for GNFT, currently valued at 0.51, compared to the broader market-4.00-2.000.002.004.006.000.51-1.55
The chart of Omega ratio for GNFT, currently valued at 1.07, compared to the broader market0.501.001.502.001.070.78
The chart of Calmar ratio for GNFT, currently valued at 0.03, compared to the broader market0.002.004.006.000.03-0.86
The chart of Martin ratio for GNFT, currently valued at 0.09, compared to the broader market0.005.0010.0015.0020.0025.0030.000.09-1.84
GNFT
MRK

The current GNFT Sharpe Ratio is 0.04, which is higher than the MRK Sharpe Ratio of -1.20. The chart below compares the historical Sharpe Ratios of GNFT and MRK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.50SeptemberOctoberNovemberDecember2025February
0.04
-1.20
GNFT
MRK

Dividends

GNFT vs. MRK - Dividend Comparison

GNFT has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 3.48%.


TTM20242023202220212020201920182017201620152014
GNFT
Genfit
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
MRK
Merck & Co., Inc.
3.48%3.14%2.72%2.52%3.41%3.03%2.48%2.60%3.36%3.14%3.43%3.12%

Drawdowns

GNFT vs. MRK - Drawdown Comparison

The maximum GNFT drawdown since its inception was -88.42%, which is greater than MRK's maximum drawdown of -68.62%. Use the drawdown chart below to compare losses from any high point for GNFT and MRK. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%SeptemberOctoberNovemberDecember2025February
-84.44%
-31.56%
GNFT
MRK

Volatility

GNFT vs. MRK - Volatility Comparison

Genfit (GNFT) has a higher volatility of 16.16% compared to Merck & Co., Inc. (MRK) at 11.13%. This indicates that GNFT's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%SeptemberOctoberNovemberDecember2025February
16.16%
11.13%
GNFT
MRK

Financials

GNFT vs. MRK - Financials Comparison

This section allows you to compare key financial metrics between Genfit and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab